Furthermore, the combination of low-dose celastrol and the inhibitor against EGFR, HGFR, or AXL resulted in stronger inhibition of CRC cell growth than each inhibitor alone, demonstrating that blocking reactive RTK signals may enhance the efficacy of low-dose celastrol against CRC cells. The gene discussed is MET; the disease is colorectal carcinoma.